Aktienanalyse zu Cocrystal Pharma Inc (COCP)COCPCocrystal Pharma Inc

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cocrystal Pharma Inc is not a strong buy at this moment due to its ongoing financial challenges, including a current price of $1.03 and a negative net income of -$2,299,000 for Q1 2026. While the stock has shown a recent positive momentum with a 5-day change of +3.47%, the lack of revenue generation and continuous losses raise concerns. The main risk lies in the company's high price-to-sales ratio of 58.37, indicating overvaluation relative to its revenue.

1 analysts cover COCP: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.